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NP Neuropathic pain 
PGB Pregabalin 
TCM Traditional Chinese medicine 
WTD Wu-tou decoction 
NF Neurotrophic factor 
NGF Nerve growth factor 
BDNF Brain-derived neurotrophic factor 
DRG Dorsal root ganglion 
SNI Spared nerve injury 
GDNF Glial cell line-derived neurotrophic factor 
CCR5 C-c chemokine receptor type 5 
CCI Chronic constriction injury 
SNL Spinal nerve ligation 
 Pae Paeoniflorin 
 Liq Liquiritin 
TNF-α Tumor necrosis factor-α 
IL-1β Interleukin-1β 
CCL2 Chemokine (C-C motif) ligand 2 
CXCL1 Chemokine (C-X-C motif) ligand 1 
ADME Absorption, distribution, metabolism, and excretion 
GFAP Glial fibrillary acidic protein 
IBA1 Ionized calcium binding adapter molecule 1 
OB Oral bioavailability 
PAPP Apparent permeability coefficient 
PWT Paw withdrawal threshold 
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Tmax Time to reach the maximum plasma concentration 
Cmax The maximum plasma concentrations 
PI3K Phosphoinositide 3-kinase 






Neuropathic pain (NP) results from lesions or diseases of the somatosensory system, 
with the major features of mechanical allodynia and thermal hyperalgesia [1].  As a 
debilitating disease, NP diminishes people’s health and decreases their quality of life. NP 
encompasses various diseases, such as peripheral diabetic neuropathy, fibromyalgia, 
postherpetic neuralgia, cancer chemotherapy-induced NP, and acute and chronic pain, with 
the total prevalence ranging from 6.9% to 10% in the general population, which continues 
to increase with the growing number of brain injury, diabetes, and cancer cases [2]. To 
date, the primary means for conservative clinical treatment of NP is pharmacotherapy. 
According to the guidelines for NP treatment, the major first-line drugs consist of tricyclic 
antidepressants, anticonvulsants and serotonin-noradrenaline uptake inhibitors such as 
pregabalin (PGB), gabapentin, and duloxetine [3]. However, due to the limited clinical 
efficacy, side effects and inadequate responses to drug treatments, only 30–40% of NP 
patients are relieved for less than 50% of their pain intensity [4]. Thus, an increasing 
number of NP patients are seeking pain-relieving drugs used in traditional Chinese 
medicine (TCM). 
Previous reports have shown that glial cells, mainly astrocytes and microglia, are 
activated along with an increase in cell number [5-7] and neurotrophic factor (NF) 
secretion [8] when NP conditions are mimicked in several classic animal models, such as 
SNL, partial sciatic nerve ligation, and chronic constriction injury. NFs have been reported 
to play important roles in the survival, growth, and maintenance of discrete populations of 
neurons in neurodegenerative disorders and spinal cord injury [9, 10]. Nerve growth factor 
(NGF) and brain-derived neurotrophic factor (BDNF) have been reported to induce the 
development of normal functional properties of sensory neurons, which results in an 
increase in their responsiveness to peripheral stimuli. Interestingly, it has been reported 
that NGF and BDNF are increased in the injured L3 dorsal root ganglion (DRG) of spared 
nerve injury (SNI) model mice. Although NGF is decreased in intact DRG neurons after 
spared nerve injury, this process may contribute to the development of NP [11]. The glial 
cell line-derived neurotrophic factor (GDNF) family was initially identified as critical for 
the survivability of dopaminergic neurons in addition to its critical role in embryogenesis 
and cellular differentiation. GDNF maintains a neuroprotective role in mature organisms 
that may promote neuroregeneration and recovery from neurological insults. As GDNF 
and artemin exert modified injury-induced neuropathic changes in the nervous system [12, 
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13], they are likely to be regarded as a potential new class of therapeutics for NP [14]. 
 
Since nerve damage can initiate inflammatory and immune responses, as evidenced 
by the upregulation of chemokines, several studies have suggested a possible mechanism(s) 
by which chemokines serve as mediators of neuron-glial communication, leading to the 
subsequent modulation of nociceptive signal transmission [15]. Notably, C-C chemokine 
receptor type 5 (CCR5) upregulation has been identified in a mouse model of chronic 
constriction injury (CCI), which mimics NP conditions [16]. In addition, knockout of 
CCR5 has been reported to suppress CCI-induced NP [16]. Therefore, NFs and CCR5 
seem to be target molecules for potential therapeutic treatment of NP. 
According to TCM theory, NP is categorized as an arthromyodynia (Bi syndrome or 
Bi Zheng), and there is plenty of evidence to show that TCM exerts a great curative effect 
on NP through an abundance of available sources and generating few side effects [17-20]. 
As a classic TCM formula, Wu-tou decoction (WTD) has been extensively used in the 
clinical treatment of NP, including chronic inflammatory pain, trigeminal neuralgia, and 
cancer-induced pain, with a total cure rate of approximately 80% [21-23]. WTD was first 
recorded in “Synopsis of the prescriptions of the golden chamber” (in Chinese, Jin Kui 
Yao Lue), and the formula is made up of five herbs, including Radix Aconiti, Herba 
Ephedrae, Radix Paeoniae Alba, Radix Glycyrrhizae and Radix Astragali. The single use 
of these five herbs has been reported to exert analgesic effects in pharmacological studies 
[24-27]. However, it remains unclear how WTD controls NP, what bioactive component(s) 
of WTD are involved in NP treatment, and whether WTD regulates the expression of 
neurotrophic factors such as NGF, BDGF, GDNF, and CCR-5 under NP conditions. Thus, 
this study aims to clarify the possible molecular mechanism(s) of the anti-NP actions of 
WTD in vivo and in vitro. 
 
In the present study, I constructed a classic spinal nerve ligation (SNL) model in rats 
and found that WTD attenuated the severity of NP symptoms by attenuating mechanical 
allodynia and thermal hypersensitivity through the inhibition of neuroinflammation in the 
SNL rats in a dose-dependent manner. In addition, I identified paeoniflorin (Pae) and 
liquiritin (Liq) as analgesic candidates for WTD-mediated anti-NP actions in SNL rats. 
Furthermore, I demonstrated that the gene expression of NGF, BDNF, GDNF, artemin, 
and CCR5 was augmented by tumor necrosis factor α (TNF-α) and interleukin 1β (IL-1β), 
whereas only CCR5 mRNA expression was increased by CCL2 or CXCL1 in primary rat 
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glial cells. Moreover, WTD, Pae, and Liq transcriptionally enhanced the expression of 
NGF, BDNF, GDNF, and artemin in TNF-α- and IL-1β-treated glial cells through PI3K- 
and PKA-dependent pathways. In contrast, the TNF-α- and IL-1β-induced CCR5 
expression was suppressed by WTD, Pae, and Liq in a PI3K- and PKA-independent 
manner. Thus, these results provide novel evidence showing that WTD exerts anti-NP 
action by predominantly increasing the production of neurotrophic factors through the 
PI3K and PKA signaling pathways in glial cells. Therefore, Pae and Liq are likely to act 








As a classic TCM formula, WTD contains five herbs that individually consist of 
specific kinds of components, and the pharmacological mechanism(s) of this formula is 
considered to involve multiple components and be multitargeted [28]. In silico, the 
combination of absorption, distribution, metabolism, and excretion (ADME) plays an 
important role in facilitating the appropriate selection of candidate drugs [29]. In addition, 
pharmacokinetic studies are necessary for drug analysis [30]. In this chapter, I evaluate 
the anti-NP actions of WTD in SNL rats and then identify the chemical profile of this 
formula in both positive and negative modes. In addition, according to the ADME activity, 
a series of components were selected for use in determining the contents of WTD. 
Furthermore, a pharmacokinetic study of the bioactive candidates in WTD was performed. 
 
1.2 MATERIALS AND METHODS 
 
1.2.1 The preparation of WTD 
WTD was prepared with herbs purchased from Beijing Tong Ren Tang Co., Ltd. 
(Beijing, China) according to the original composition recorded in the Chinese 
Pharmacopoeia 2015 edition. In brief, the five traditional drugs were separately soaked in 
pure water for 1 h. Then, the herb mixture was added to boiling pure water at a ratio of 
1:10 (g/v) and boiled for 30 min. After collecting the filtrates, the residues were decocted 
in pure water for 20 min at a ratio of 1:5 (g/v) and then subjected to filtration. The collected 
filtrates were lyophilized (1 g of lyophilized WTD powder is equal to 3.71 g of raw 
medicinal WTD herbs) and kept at −20°C. 
 
1.2.2 The construction of the SNL model 
After three days of adaptive feeding, normal rats underwent SNL surgery. In brief, 
the rats were anesthetized by isoflurane inhalation anesthesia. To expose the L5 spine 
nerve clearly, the transverse process of the sixth left lumbar was cut off. The L5 nerve was 
carefully separated and tightly ligated with a surgical suture followed by washing the skin 
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with normal saline and suturing. Rats in the Sham group underwent surgery but L5 nerve 
remained unligatured. The study protocol was designed according to Declaration of Helsinki 
principles. The study was approved by the Ethics Committee of the Institute of Chinese Materia 
Medica, China Academy of Chinese Medical Sciences (Registration No. 2018-098). 
 
1.2.3 Measurement of mechanical hypersensitivity 
The rats were acclimatized in individual clear boxes on a wire-mesh platform to allow 
access to the ventral surface of the hind paws. Mechanical hypersensitivity was estimated 
by rat sensitivity to the stimulation of von Frey hairs. The von Frey filaments (1.0-100.0 g) 
were presented perpendicular to the plantar surface of the injected paw and held in this 
position for 5-8 s with enough force to cause a slight bend in the filament. Positive 
responses included an abrupt withdrawal of the hind paw or flinching behavior 
immediately following removal of the stimulus. A median paw withdrawal threshold was 
decided according to an adaptation of Dixon's up-down method. The 50% paw withdrawal 
threshold was analyzed at 0, 0.5, 1, 1.5, 2, and 3 h and 2 and 3 days after drug 
administration. 
 
1.2.4 Measurement of cold hypersensitivity 
Briefly, 20 µL of acetone was sprayed gently on the middle of the plantar surface of 
the hind paw with a 1 mL syringe from a short distance. The number of times that rats 
licked and/or shook the hind paw for 5 min after acetone application was recorded and 
used as an index of responsiveness to cold hypersensitivity. The licking and/or shaking 
times were measured at 0, 0.5, 1, 1.5, 2, and 3 h and 2 and 3 days after drug administration. 
 
1.2.5 The identification of cell types in the spinal cord of SNL rats 
Glial cells activated by peripheral nerve injury contribute to the induction and 
maintenance of NP by releasing neuromodulating cytokines and chemokines [31]. Thus, 
the distribution of microglial cells and astrocytes in the spinal cord of rats was examined 
by immunofluorescence staining with antibodies against ionized calcium-binding adapter 
molecule 1 (IBA1) and glial fibrillary acidic protein (GFAP), respectively. After drug 
treatments, the rats were deeply anesthetized with sodium pentobarbital and rapidly 
perfused transcardially with 0.9% saline followed by 0.16 M PB (4°C, pH=7.4, 10 min) 
containing 4% paraformaldehyde and 1.5% picric acid. After perfusion, the L5 spinal cord 
 
8 
segments were removed and postfixed in the same solution for 4 h and then cryoprotected 
in 0.1 M PB containing 15% and 30% sucrose for 24-48 h at 4°C, respectively. Spinal cord 
sections (18 µm, free-floating) were cut in a cryostat (Leica Biosystems) and deposited in 
cryoprotectant at -80°C. 
When testing, the sections were rinsed in PBS (pH=7.2-7.4) 3 times (15 min each 
time) and blocked with 8% goat serum or BSA in 0.5% Triton X-100 (Life Sciences) for 
2 h at room temperature. Then, the prepared sections were incubated in blocking solution 
for 12 h at 4°C with primary antibodies against glial fibrillary acidic protein (anti-GFAP1, 
1:200, anti-rabbit, Abcam) and ionized calcium-binding adapter molecule 1 (anti-IBA1, 
1:100, anti-rabbit, Abcam). After equilibrating at room temperature for one-half hour, the 
sections were incubated for 1 h at 37°C with an Alexa Fluor® 594 (1:200, anti-rabbit, 
Abcam)-conjugated secondary antibody. After incubation in DAPI (0.5 μg/mL, Sigma 
Aldrich, St. Louis, MO) in PBS for 6 min and rinsing with PBS (containing 0.1% Tween-
20) 3 times (15 min each time), the stained sections were dried, and images were examined 
with FV10-ASW-4.0 software (Olympus, Tokyo, Japan). 
 
1.2.6 Determination of chemical compounds of WTD  
To systematically analyze the chemical compounds in WTD, I constructed the 
chemical profile of the WTD using HPLC. First, a simple and effective UHPLC-ESI-
LTQ/Orbitrap MSn protocol was developed as a sensitive, reliable, and high-throughput 
method for the rapid identification of the components of WTD regardless of their 
abundance as macro- and microconstituents. In the HPLC-ESI-MSn spectra, most of the 
compounds were identified by their quasi-molecular ions [M+H]+, [M+Na]+ or [M+K]+ in 
positive ion mode or by [M-H]− or [M+HCOO]− in negative ion mode. The compounds 
were identified as standard available compounds by comparing the retention time and 
accurate high-resolution mass, and for the standard unavailable compounds, the structures 
were presumed based on the following steps to increase the credibility of the findings: (1) 
the molecular formula was established based on a highly accurate quasi-molecular ion 
such as [M+H]+, [M+Na]+, [M-H]-, or [M+HCOO]- within a mass error of 5 ppm and the 
fractional isotope abundance; and (2) the most rational molecular formula was searched in 
chemical databases, such as ChemSpider (www.chemspider.com) and Massbank 
(http://www.massbank.jp). When there were several matching isomers, the structures were 
searched in a chemical information database that includes the composition of WTD. 
Moreover, the authenticity of the identification of the compounds from the crude 
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individual drugs was confirmed by comparing the corresponding extracted ion 
chromatogram of WTD with those of the single constituent drugs. 
 
1.2.7 Absorption distribution-metabolism-excretion evaluation of chemical compounds 
contained in WTD 
Structural information (*.mol or *.sdf files) relating to the DB components (identified 
by UPLC-ESI-MS/MS) was downloaded from ChemSpider 
(http://www.chemspider.com/). The Absorption distribution metabolism excretion 
(ADME) evaluation of these constituents was carried out using ACD/Percepta software 
5.07 (ACD/Labs, Toronto, Canada), including the passive intestinal permeability of the 
Caco-2 module and the PK explorer module to predict their oral bioavailability. The 
apparent permeability coefficient (Papp) of one constituent was greater than 1.0 x 10-6 
cm/s and 40%, which indicated drug-like characteristics. 
 
1.2.8 Statistical analysis 
Statistical analyses were conducted by SPSS statistical software. For all quantification 
analyses, one-way ANOVAs were used. P-values less than 0.05 were considered 




1.3.1 WTD attenuated SNL-induced mechanical allodynia and cold hyperalgesia 
 
To determine whether WTD attenuates SNL-induced NP, different doses (3.75, 7.5, 
and 15 g/kg) of WTD were orally administered once per day for 3 consecutive days, and 
then, the behavioral assessment was performed 1 h after each drug treatment. As shown in 
Fig. 1-1A, SNL markedly reduced the 50% paw withdrawal threshold (PWT) compared 
with that in the control (Con) group (p<0.001). In contrast to the SNL group, all treatment 
groups, including WTD-Low, WTD-Middle, and WTD-High, and PGB attenuated 
mechanical allodynia, which lasted for at least 2 h, with an optimal inhibitory effect at 1 
h post-WTD administration. Thus, 1 h post-WTD administration was selected as the 
optimal time point for further detection, which was in accordance with our previous 
findings [32]. In addition, compared with normal rats, rats that underwent SNL surgery 
were more sensitive to cold stimuli (p <0.05, Fig. 1-1B), with increased reaction times to 
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acetone stimuli. However, after treatment with WTD at middle and high doses and PGB, 
the reaction times of the SNL rats to the cold stimulus markedly decreased (p<0.05). In 
addition, there was no significant difference between the WTD and PGB group in terms 
of the improvement of the 50% PWT and reduction in the reaction times of SNL rats to 
cold stimulus. 
 
1.3.2 Astrocytes and microglia tended to increase in the spinal cord of rats 
 
GFAP and IBA1 are cell markers of astrocytes and microglia, respectively [33, 34]. 
In this study, I found that the signal intensity of GFAP and IBA1 tended to be enhanced 
in the spinal cord of SNL rats under NP conditions, indicating an increased number of 
astrocytes and microglia. This result was in accordance with our previous study showing 
that WTD exerted analgesic action through an inhibitory effect on the activation of glial 
cells, including astrocytes and microglia [35]. Thus, an in vitro experiment using primary 
rat glial cells was performed to clarify the molecular mechanism(s) of WTD-induced 









Figure 1-1 Anti-hyperalgesia effects of WTD against NP. Spinal nerve ligation (SNL) 
induced obvious mechanical allodynia and cold hyperalgesia in rats. WTD (7.5-15 
g · kg-1) markedly reversed SNL-induced mechanical allodynia (A) and cold 
hyperalgesia (B), and the anti-hyperalgesic effects of high-dose WTD (15 g · kg-1) were 
similar to those of PGB (100 mg · kg-1, p.o.). n = 6, x ± SD. #, ##, and ###, P<0.05, 0.01 
and 0.001 vs. the Sham group (Sham), respectively. *, **, and ***, P<0.05, 0.01 and 0.001 







Figure 1-2 Immunofluorescent staining of astrocytes and microglial cells in spinal 
cord tissues from normal and SNL rats. In contrast with the control group, the signal 
intensity of both GFAP and IBA1 was enhanced in the spinal cord of the SNL rats, indicating 







 1.3.3 Identification of the major bioactive compounds of WTD in the treatment of NP 
 
Table 1-1 shows that 77 components were identified in WTD, and five single herbs 
were present in WTD. Among these compounds, 13 compounds, 4, 5, 19, 37, 38, 42, 54, 
58, 71, 72, 73, 76, and 77, were identified as albiflorin, paeoniflorin (Pae), liquiritin 
(Liq), calycosin, formononetin, protocatechuic acid, rutin, cinnamic acid, 
benzoylmesaconine, benzoylaconitine, benzoylhypacoitine, hypaconitine, and aconitine, 
respectively, by comparing the retention time and high-resolution accurate mass. For the 
standard unavailable compounds, the structures were presumed by comparison with a 
previous study or seeking the most rational molecular formula in chemical databases, 
such as ChemSpider (www.chemspider.com) and Massbank (http://www.massbank.jp). 
When there were several matching isomers, the structures were sought in a chemical 
information database containing the composition of WTD. In addition, the authenticity 
of the identification of the compounds from the individual crude drugs was confirmed 
by comparing the corresponding extracted ion chromatogram (XIC) of WTD with those 
of single constituent drugs. Forty-three of the 77 compounds were identified as 
candidate bioactive compounds with potential druggability by ADME evaluation in 
silico. In addition, Pae and Liq, which are known to be effective for NP control [36, 37], 
were found to be in these compounds. Furthermore, LC-MS analysis revealed that the 




Table 1-1 Characterization of the chemical constituents of WTD and five single herbs by HPLC-ESI-LTQ-MS 
 
NO Rt Identification 








(%F) Indicated ppm Indicated ppm 







589.12225 0.15 — — C24H30O15S 590 421.16[M-H-C7H5O5]- 0.2 10.0 





4 26.24 Albiflorin 525.15912 2.19 503.14975 5.24 C23H28O11 480 479.23[M+CHO2-H]- 0.3 13.9 





















647.14252 0.59 — — C30H32O14S 648 — 40.0 99.7 










11 4.7 Citric acid 191.01944 4.25 215.01599 1.09 C6H8O7 192 172.86[M-H-H2O]- 0.0 0.2 























16 26.34 Liquiritin apioside 549.16046 0.35 — — C26H30O13 550 255.05[M-H-C15H18O6]- 0.1 9.2 
17 26.61 Glucoliquiritin apioside 711.21301 0.26 — — C32H40O18 712 — 0.0 0.04 
18 30.9 Vicenin-2 593.15002 0.13 — — C27H30O15 594 473.12[M-H-C4H8O4]- ; 0.0 0.04 





20 36.26 Liquiritigenin 255.06522 0.14 257.07996 3.4 C15H12O4 256 134.80[M-H-C4H8O4]- 174.0 99.2 



























879.39929 1.82 903.39453 4.38 C44H64O18 880 351.16[M-H-C22H40O14]- 0.0 0.00009 










29 4.67 Isomucronulatol — — 303.12903 1.5 
C10H22O10 
C17H18O5 
302 — 188.0 98.6 
30 20.49 Rhamnocitin/isomeride 299.05548 1.57 — — C16H12O6 300 — 18.0/18.0 99.2/99.2 










379.16519 0.11 — — C22H24N2O4 380 297.16[M-H-C5H8N]- 13.0 78.0 
33 38.43 Rhamnocitin/isomeride 299.05566 2.17 — — C16H12O6 300 283.94[M-H-CH3]- 18.0/18.0 99.2/99.2 































277.09235 2.00 — — C11H18O8 278 114.90[M-H-C6H10O5]- 244.0 97.2 
40 10.53 p-Hydroxybenzoic acid 137.02448 8.46 — — C7H6O3 138 92.85[M-H-CHO2]- 5.0 80.6 
41 11.8 p-Hydroxybenzoic acid 137.02455 8.97 — — C7H6O3 138 92.85[M-H-CHO2]- 5.0 80.6 
42 13 Protocatechuic acid 153.01913 5.85 — — C7H6O4 154 — 3.0 63.2 












45 21.01 Leucopelargonidin 289.07132 2.30 — — C15H14O6 290 245.00[M-H-CO2]-；  2.0 64.6 






























163.03998 6.20 — — C9H8O3 164 118.82[M+H-CO2]- 5.0 86.5 












54 38.05 Rutin 609.14459 0.69 — — C27H30O16 610 447.15[M-H-CH6O9]- 0.0 0.1 



















58 49.47 Cinnamic acid 147.04515 7.44 — — C9H8O2 148 102.92[M-H-CO2]- 27.0 99.1 

















63 16.75 Talatizidine — — 408.27290 3.79 C23H37O5N 407 — 20.0 87.7 










66 22.31 Bullatine B/isomeride — — 438.28268 5.33 C24H39NO6 437 — 4.0/4.0 51.0/51.0 
67 22.7 Talalisamine — — 422.28857 3.63 C24H39NO5 421 — 20.0 87.7 












































— — 648.29990 2.44 C33H45NO12 647 588.47[M+H-C2H4O2]+ 9.0/14.0 96.4/98.5 




77 46.28 Aconitine  — — 646.32030 2.91 C34H47NO11 645 566.43896[M+H-C5H5O]+ 45.0 99.6 
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1.3.4 Analgesic action of Pae and Liq in a rat SNL model 
 
To evaluate the analgesic action of WTD and its bioactive compounds Pae and Liq, 
I evaluated the 50% PWT and the reaction times to acetone stimulation. In this 
experiment, the dosage of WTD was 15 g/kg, which was approximately 4-fold higher 
than the clinical daily dose. Based on the dosage, experiments were performed with the 
single use of Pae and Liq at 37.3 and 15.1 mg/kg, respectively, and the combination of 
Pae and Liq (Pae+Liq) at the same dose. PGB was used as the positive control at 100 
mg/kg, which was approximately 4-fold higher than the clinical daily dose. As shown in 
Fig. 1-3, SNL was found to cause mechanical allodynia and cold hyperalgesia, in contrast 
to rats in the Sham group (p<0.001). Compared with the SNL group, all treatment groups, 
including the WTD, Pae+Liq, Pae, Liq, and PGB groups, significantly attenuated 
mechanically induced allodynia at all time points (p<0.05). However, there was no 
difference between WTD and PGB treated SNL rats regarding the improvement of 50% 
PWT or reduction in the reaction times to cold stimulus. In addition, the pharmacological 
effect of the combination of Pae and Liq showed no marked difference from that of WTD. 
The pharmacokinetics and pharmacological actions of the combination of Pae and Liq 
were determined and compared with those of WTD by UPLC-MS/MS. The tissue distribution 
of Pae and Liq after a single treatment with Pae+Liq (equal content to WTD at 0.75 g/mL) or 
WTD (0.75 g/mL) in the plasma of normal rats was determined at four time points: 5, 30, 120, 
and 360 mins post oral administration. The mean concentration-time curves of Pae and Liq are 
shown in Fig. 1-4. The main pharmacokinetic parameters of Pae and Liq are summarized in 
Table 1-2. As shown in Fig. 1-4, the time to reach the maximum plasma concentration (Tmax) 
for both Pae and Liq after the administration of Pae+Liq was 5 min, which was less than that 
of WTD (120 min and 30 min for Pae and Liq, respectively), indicating the rapid absorption 
of Pae+Liq. The maximum plasma concentrations (Cmax) of Pae (668 ng/mL) and Liq (17.1 
ng/mL) in rats administered Pae+Liq were approximately 4.6-fold and 1.3-fold higher than 





Figure 1-3 Anti-hyperalgesia effects of WTD and its bioactive compounds Pae and 
Liq against NP. Spinal nerve ligation (SNL) mechanically induced obvious allodynia 
and cold hyperalgesia in rats. WTD (15 g/kg) and its bioactive compounds Pae and Liq 
alone or in combination markedly reversed SNL-induced mechanical allodynia (A) and 
cold hyperalgesia (B). The anti-hyperalgesic effects of Pae+Liq were similar to those of 
WTD (15 g/kg). The data are shown as the means ± SD. ###, P<0.001 vs. the Sham group 









Figure 1-4 The plasma concentrations of Pae and Liq after a single administration 
of WTD or Pae+Liq. The time to reach the maximum plasma concentration for both Pae 
and Liq after the administration of Pae+Liq was 5 min, while the time was 120 min and 
30 min for Pae and Liq, respectively, after treatment with WTD, indicating the rapid 
absorption of Pae+Liq. The maximum plasma concentrations of Pae and Liq after the 
administration of Pae+Liq were 668 ng/mL and 17.1 ng/mL, respectively; however, they 
were 144 ng/mL and 13.3 ng/mL, respectively, in rats administered WTD, indicating an 












Pae Liq Pae Liq 
Cmax (ng/mL) 628 ± 412 46.5 ± 43.6 198 ± 67.7 21.1 ± 9.8 
Tmax (h) 0.3 ± 0.1 1.5 ± 2.6 0.9 ± 0.2 0.4 ± 0.2 
AUClast 
(ng∙h/mL) 
1231 ± 343 100 ± 33 1022 ± 155 92.9 ± 23.5 
AUCINF_obs 
(ng∙h/mL) 
1307 ± 393 122 ± 24.3 1174 ± 129 168 ± 137 
HL_lamda_Z (h) 5.7 ± 3.4 10.1 ± 4.0 9.1 ± 3.4 24.7 ± 35.5 





In recent years, it was reported that glia in the peripheral and central nervous systems play 
critical roles in the onset and maintenance of NP [38]. In addition, the increased activation of 
satellite glial cells, astrocytes, and microglia in the dorsal root ganglia, spinal cord, and brain 
of oxaliplatin-induced NP animals has been proven using in vivo experiments with rodents 
[39]. In the clinic, approximately one-half of the patients with spinal cord injury have been 
reported to develop debilitating central NP with no effective treatments [40]. A recent report 
has shown that inhibition of glial activation regulated by fatty acids prevents central NP after 
spinal cord injury [41]. Furthermore, it has been reported that the activation of glial cells 
mediates long-term potentiation induction in the spinal cord following peripheral nerve injury, 
which affects the excitability of neurons with a wide dynamic range in the dorsal horn of the 
spinal cord [42]. Since changes in the environment of astrocytes under inflammation exert 
critical roles in the onset and progression of NP, a recent study reported a possible mechanism 
by which the inflammation-mediated modulation of G protein signaling regulators constitutes 
an adaptive mechanism in the context of neuroinflammation, which might mediate the 
regulation of nociception [43]. Moreover, it has been reported that drugs that inhibit L5-SNL-
induced microglial proliferation and activation offer potential therapeutic strategies for NP 
treatment [44]. Thus, to determine how glial cells function upon WTD treatment, the 
mechanisms of the pharmacological actions of WTD, Pae, and Liq are very important to 
discern. 
It has been reported that various cytokines and chemokines are increased with the 
development of NP under inflammatory conditions [45, 46]. In addition, our previous 
studies have shown that WTD treatment clearly decreases the expression levels of IL-1β, 
CCL2, and CXCL1 in the spinal cord dorsal horn in SNL mice in a dose-dependent 
manner [35]. In the present study, I demonstrated that WTD effectively attenuated the 
severity of NP symptoms by attenuating the mechanical allodynia and thermal 
hypersensitivity in SNL rats. Therefore, microarray and network analyses in the SNL 
model may be strategies to understand the molecular mechanisms of WTD against NP. 
These experiments seemed to indicate substantial target molecules in WTD that are 
functionally enriched in several glial cell activation-related and neuroinflammatory 
pathways in SNL-induced NP. 
I have identified the anti-pain effect of Pae and Liq by regulating the chemokine signaling 
pathway in the spinal cord dorsal horn of SNL rats. Pae is a bioactive compound purified 
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from a Chinese herb, Radix Paeoniae Alba (Bai shao, in Chinese), that exhibits anti-
inflammation, enhancing immunity and conferring neuroprotective effects [47]. Liq is an 
active component extracted from Radix Glycyrrhizae (Gan cao, in Chinese) that exhibits 
a potential neuroprotective effect [48] and anti-inflammatory action [49-51]. Recently, it 
has been reported that the activation of the NLRP3 inflammasome mediates the development 
of NP following chronic constriction injury (CCI) of the sciatic nerve. In addition, Pae has 
been reported to attenuate NP by inhibiting neuroinflammation through the suppression of 
NLRP3 inflammasome activation and the enhancement of nuclear factor erythroid 2-related 
factor 2 translocation into the nucleus, which in turn suppresses nuclear factor-kappa B 
activity in the spinal cord. Furthermore, Zhou et al. reported the mechanisms of Pae against 
neuroinflammation: i) inhibition of ASK1 phosphorylation, ii) reduction in the expression of 
phosphorylated p38 and JNK, iii) diminished response of astrocytes and microglial cells to 
injury, and iv) suppression of the expression of IL-1β and TNF-α in the CCI model [52]. On 
the other hand, the neuroprotective effect of Liq has recently received much attention. It has 
been reported that Liq exerts a neuroprotective effect on CCI-induced NP by restoring injured 
axons and myelin sheaths, inhibiting the activation of astrocytes and microglia, 
downregulating the expression of proinflammatory cytokines such as TNF-α, IL-6, and IL-
1β, and simultaneously upregulating that of the anti-inflammatory cytokine IL-10 [48]. 
In summary, these results strongly suggest that WTD is an effective therapeutic formula 
for NP and that its pharmacological activity is mostly due to Pae and Liq, both of which have 





Pharmacological Mechanisms of the Anti-NP Actions of WTD, Pae, and Liq 




It has been reported that glial cells play important roles during the onset and 
progression of NP due to the increase in cell number and the secretion of neurotrophic 
factors (NFs) and chemokines in several classic NP animal models, such as SNL, partial 
sciatic nerve ligation, and chronic constriction injury [5-8, 31, 53-55, 59-63]. In addition, 
our previous study showed that the levels of TNF-α, IL-1β, CCL2, and CXCL1 were 
increased in the spinal cord of rats that underwent SNL surgery [32]. Furthermore, the 
upregulation of BDNF, GDNF, and NGF expression has been reported to occur in a 
phosphoinositide 3-kinase (PI3K)- and PKA-dependent manner in BV-2 microglial cells 
[56-58]. On the other hand, in Chapter 1, I show that Pae and Liq are analgesic candidates 
for WTD-mediated anti-neuropathic actions in SNL-induced NP rats. However, how WTD, 
Pae, and Liq control NP remains unclear. Thus, this chapter aims to clarify the possible 
pharmacological mechanism of the anti-NP actions of WTD, Pae, and Liq in primary rat 
glial cells. To this end, I performed inhibitor experiments with LY294002 and H89, which 
are specific inhibitors against phosphatidylinositol-3 kinase (PI3K) and protein kinase A 
(PKA), respectively [64], to evaluate the regulation of NF expression by WTD, Pae, and 
Liq in primary rat glial cells in the presence or absence of TNF-α, IL-1β, CCL2, or 
CXCL1 in vitro. 
 
2.2 MATERIALS AND METHODS 
 
2.2.1 Materials 
Pae (CAS: 23180-57-6) and Liq (CAS: 551-15-5) were purchased from Shanghai 




LTQ-Orbitrap-MS). The water extract of WTD was prepared according to the quality 
control standards of the China Pharmacopoeia as described in Chapter 1 and then 
lyophilized (1 g of lyophilized WTD powder is equal to 3.71 g of raw medicinal WTD 
herbs). TNF-α (recombinant rat TNF-α, Cat. No. 510-RT-010), IL-1β (recombinant rat 
IL-1β, Cat. No. 501-RL-010/CF), and CCL2 (recombinant rat CCL2/JE/MCP-1, Cat. No. 
3144- JE) were purchased from R&D Systems (Minneapolis, MN, USA). CXCL1 
[recombinant rat GRO/KC (CXCL1), Cat. No. 400-10] was purchased from PeproTech, 
Inc. (Rocky Hill, USA). A PI3K inhibitor, LY294002 (Cat. No. 70920), and a PKA 
inhibitor, H89 (Cat. No. A11935), were purchased from Cayman Chemical Company, Inc. 
(MI, USA) and AdooQ BioScience (Irvine, CA), respectively. 
 
2.2.2 Cell culture and treatments 
Primary glial cells were prepared according to our previous study with modifications 
[54]. Briefly, the cerebral cortex of 4-5 newborn SD rats [2-4 days old (sex unconfirmed), 
housed at 22-24°C in a room with a constant humidity of 50-60% and a regular 12-h 
light/12-h dark cycle together with dams] was removed and digested by 0.25% trypsin 
and 0.4% DNase in PBS (Wako Pure Chemical Industries, Inc., Tokyo, Japan). 
Dissociated glial cells were cultured in 100 cm2 dishes (Bio-REV Pte. Ltd., Singapore, 
Singapore) in DMEM containing 10% FBS in a humidified atmosphere with 5% CO2 at 
37°C. The medium was changed to remove unattached cells 2 days after seeding. Then, 
the primary glial cells needed another 7-9 days to reach confluence before harvesting 
from the dish by 0.25% trypsin treatment. Subsequently, the cells were seeded at a density 
of 4 x 105 cells/mL in 12-well plates and allowed to grow to 80-90% confluence. The 
ratio of astrocytes and microglia in these primary glial cells was approximately 76% and 
24%, respectively. Primary glial cells were treated with or without WTD (3.2, 16, and 80 
µg/mL), Liq (5, 10, and 20 µg/mL), or Pae (50, 100, and 200 µg/mL) in the presence or 
absence of TNF-α (1 and 10 ng/mL), IL-1β (1 and 10 ng/mL), CCL2 (100 ng/mL), 
CXCL1 (312 ng/mL), LY294002 (1, 5, and 10 mM), and H89 (1, 5, and 10 mM). The 
present study was approved by the Committee of Animal Care and Welfare of Tokyo 





2.2.3 Cell viability 
Primary glial cells (1 x 104 cells) were seeded on a 96-well plate and cultured for 24 
h. The cells were treated for an additional 24 h with WTD (3.2-2000 µg/mL), Pae (0.06-
6000 µg/mL), or Liq (0.04-400 µg/mL) following a change to fresh culture medium. Cell 
viability was determined by using CellTiter-Blue® (Promega, Tokyo, Japan) (excitation 
at 535 nm and emission at 595 nm). 
 
2.2.4 RNA isolation and quantitative RT-PCR 
Total RNA was isolated from cells by ISOGEN (Nippon Gene, Toyama, Japan) 
according to the manufacturer’s instructions and then quantified by a NanoDrop 
spectrophotometer (ND-1000; Wilmington, DE, USA). An aliquot of total RNA (500 ng) 
was subjected to cDNA synthesis using a PrimeScript RT Reagent Kit (TaKaRa Bio, 
Shiga, Japan) according to the manufacturer’s instructions. Transcripts (an equivalent of 
25 ng of total RNA) were used for real-time PCR using SYBR Premix Ex Taq II (TaKaRa 
Bio) and specific primers for NGF, BDNF, GDNF, artemin, and CCR5 (detailed 
information is provided in Table 2-1). Amplification was performed at 94°C for 5 s and 
60°C for 30 s in a TP-800 Thermal Cycler Dice Real Time System (TaKaRa Bio). The 
obtained threshold cycle (CT) of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
was used to normalize and quantify NGF, BDNF, GDNF, artemin, and CCR5. The 
relative expression level was calculated by the ΔCT method with the CT value of GAPDH. 
 
2.2.5 ELISA 
ELISA was performed using ELISA kits for NGF (Thermo Fisher Scientific, 






































2.2.6 Statistical analysis 
Statistical analysis was performed using one-way analysis of variance, followed by 
the Tukey-Kramer test with SPSS software (Version 19.0). The data were presented as 








2.3.1 NGF, BDNF, GDNF, artemin, and CCR5 mRNA expression is regulated by 
inflammatory cytokines and chemokines in primary rat glial cells 
As cytokines and chemokines play an important role in the coordination of immune 
responses throughout the body, especially within the nervous system under pathological 
conditions, they can lead to the activation of glial cells, which is a vital step under NP 
conditions [55]. In this experiment, I investigated the effects of TNF-α, IL-1β, CCL2, 
and CXCL1 on the gene expression of NGF, BDNF, GDNF, artemin, and CCR5 in rat 
glial cells. As shown in Fig. 2-1, TNF-α and IL-1β were found to increase the mRNA 
expression levels of NGF, BDNF, GDNF, artemin, and CCR5. In addition, CCL2 and 
CXCL1 augmented the gene expression of CCR5 but not that of NGF, BDNF, GDNF, or 
artemin in rat glial cells (Fig. 2-2). These results suggested that the expression of NFs 
and/or CCR5 was upregulated by TNF-α, IL-1β, CCL2, and CXCL1 in primary rat glial 
cells, whereas neither CCL2 nor CXCL1 was involved in the regulation of glial NF 
expression. 
 
2.3.2 WTD, Pae, and Liq enhance NGF, BDNF, GDNF, and artemin but decrease CCR5 
expression in primary rat glial cells 
To elucidate the molecular mechanisms of anti-NP action by WTD, Pae, and Liq, I 
next examined whether these compounds influence the expression of NFs and CCR5 in 
rat glial cells. As shown in Fig. 2-3, WTD, Pae, and Liq augmented the mRNA expression 
of NGF, BDNF, GDNF, and artemin in a dose-dependent manner. In addition, IL-1β-
augmented NGF, BDNF, GDNF, and artemin expression was enhanced by WTD, Pae, 
and Liq in rat glial cells in a dose-dependent manner. Furthermore, the transcriptional 
augmentation of NGF and BDNF expression led to an increase in their protein levels (Fig. 
2-4). In contrast, both constitutive and IL-1β-augmented CCR5 mRNA expression was 
suppressed by WTD, Pae, and Liq in a dose-dependent manner. Moreover, there was no 
change in the viability of the glial cells, even when the cells were treated with WTD (3.2-




that these reagents may induce no cytotoxicity at the concentrations used in this 
experiment. Therefore, these results suggest that WTD, Pae, and Liq transcriptionally 








Figure 2-1 Augmentation of NF and CCR5 gene expression by TNF-α and IL-1β in 
rat glial cells. TNF-α (10 ng/mL) and IL-1β (10 ng/mL) increased the gene expression 
of NGF (A), BDNF (B), GDNF (C), artemin (D), and CCR5 (E) in rat glial cells. *, **, 














Figure 2-2 Differential regulation of NF and CCR5 gene expression by CCL2 and 
CXCL1 in rat glial cells. CCL2 (100 ng/mL) and CXCL1 (312 ng/mL) showed no 
significant effect on the gene expression of NGF (A), BDNF (B), GDNF (C), or artemin 
(D) in rat glial cells. However, both chemokines significantly augmented CCR5 gene 












Figure 2-3 Effects of WTD, Pae, and Liq on the gene expression of NGF, BDNF, 
GDNF, artemin and CCR5 in rat glial cells. When glial cells were treated with WTD, 
Pae, and Liq, the mRNA expression of neuroprotective factors such as NGF (A, F, and 
K), BDNF (B, G, and L), GDNF (C, H, and M), and artemin (D, I, and N) was increased 
in a dose-dependent manner. In addition, the IL-1β-augmented gene expression of NGF, 
GDNF, and artemin was enhanced by WTD, Pae, and Liq. However, constitutive and IL-
1β-induced CCR5 mRNA expression (E, J, and O) was suppressed by WTD, Pae, and Liq 
in rat glial cells. *, **, and ***, significantly different from untreated cells (Con) (p<0.05, 
0.01, and 0.001, respectively). #, ##, and ###, significantly different from IL-1β-treated 








Figure 2-4 Increase in NGF and BDNF production by WTD, Pae, and Liq in IL-1β-
treated rat glial cells. When glial cells were treated for 24 h with IL-1β (10 ng/mL), the 
production of NGF (A) and BDNF (B) was increased. The IL-1β-increased NGF and 
BDNF production was further enhanced by WTD (80 µg/mL), Pae (200 µg/mL), and Liq 
(20 µg/mL) in rat glial cells. * and ***, significantly different from untreated cells (Con) 






Figure 2-5 No cytotoxicity was induced by WTD, Pae, or Liq in primary rat glial 
cells. CellTiter-Blue assays were performed in primary rat glial cells treated with WTD 





2.3.3 Involvement of the PI3K and PKA pathways in the WTD-, Pae-, and Liq-augmented 
expression of NFs in primary rat glial cells 
As shown in Fig. 2-6, WTD-augmented NGF, BDNF, GDNF, and artemin gene 
expression was inhibited in a dose-dependent manner by adding LY294002 (10 µM) (48.2, 
61.5, 39.9, and 47.7% inhibition vs. WTD treatment, respectively). In addition, similar 
inhibition by LY294002 (10 µM) was observed in the Pae- and Liq-increased gene 
expression of NGF, BDNF, GDNF, and artemin (27.7, 22.9, 23.1, and 36.6% inhibition 
vs. Pae treatment, respectively, and 17.0, 37.3, 40.4, and 51.3% inhibition vs. Liq 
treatment, respectively). Furthermore, the WTD-, Pae-, and Liq-augmented production of 
NGF and BDNF was decreased in LY294002 (10 µM)-treated rat glial cells (Fig. 2-7) 
Regarding the PKA pathway, Fig. 2-8 revealed that the mRNA levels of NGF, BDNF, 
GDNF, and artemin were decreased by H89 (10 µM) in the WTD-treated cells in a dose-
dependent manner (25.3, 44.2, 35.5, and 38.7% inhibition vs. WTD treatment, 
respectively). NGF, BDNF, GDNF, and artemin gene expression was similarly inhibited 
by H89 (10 µM) in both Pae- and Liq-treated glial cells (30.3, 27.0, 33.0, and 39.0% 
inhibition vs. Pae treatment, respectively, and 26.4, 27.0, 29.8, and 39.0% inhibition vs. 
Liq treatment, respectively). Furthermore, the production of NGF and BDNF was 
suppressed by H89 (10 µM) in WTD-, Pae-, and Liq-treated rat glial cells (Fig. 2-7). 
Therefore, these results suggested that WTD-, Pae-, and Liq-augmented NGF, BDNF, 
GDNF, and artemin expression was associated with the activation of the PI3K and PKA 







Figure 2-6 The involvement of PI3K in WTD-, Pae-, and Liq-enhanced NF expression in 
rat glial cells. The increased mRNA expression of neuroprotective factors such as NGF (A, E, 
and I), BDNF (B, F, and J), GDNF (C, G, and K), and artemin (D, H, and L) induced by WTD 
(80 μg/mL), Liq (200 μg/mL), and Pae (20 μg/mL) was suppressed by LY294002 (1-10 μM) 
in a dose-dependent manner. *, **, and ***, significantly different from untreated cells (Con) 
(p<0.05, 0.01, and 0.001, respectively). #, ##, and ###, significantly different from WTD-, Pae-, 








Figure 2-7 The PI3K- and PKA-dependent augmentation of NGF and BDNF production 
by WTD, Pae, and Liq in rat glial cells. ELISA with harvested culture medium shows that 
the augmented production of NGF (A) and BDNF (B) by WTD, Pae, and Liq was decreased 
by adding LY294002 (10 μM) (A) and H89 (10 μM) (B). *, **, and ***, significantly different 
from untreated cells (Con) (p<0.05, 0.01, and 0.001, respectively). # and ##, significantly 









Figure 2-8 The involvement of PKA in WTD-, Pae-, and Liq-enhanced NF expression in 
rat glial cells. The increased mRNA expression of NGF (A, E, and I), BDNF (B, F, and J), 
GDNF (C, G, and K), and artemin (D, H, and L) by WTD (80 µg/mL), Liq (200 µg/mL), and 
Pae (20 µg/mL) was suppressed by H89 (1-10 µM) in a dose-dependent manner. *, **, and ***, 
significantly different from untreated cells (Con) (p<0.05, 0.01, and 0.001, respectively). #, ##, 








2.3.4 Neither the PI3K nor the PKA signaling pathway was involved in the WTD-, Pae-, 
and Liq-mediated suppression of CCR5 expression in rat glial cells 
I further examined the effects of LY294002 and H89 on CCR5 downregulation by 
WTD, Pae, and Liq in rat glial cells. As shown in Fig. 2-9, when the cells were treated 
with WTD, Pae, and Liq in the presence of LY294002 (10 µM), there was no change in 
the level decrease in CCR5 mRNA. In addition, H89 (10 µM) administration did not alter 
CCR5 expression in WTD-, Pae-, and Liq-treated cells, indicating that neither the PI3K 
nor the PKA pathway was required for the WTD-, Pae-, and Liq-mediated suppression of 






Figure 2-9 Neither PI3K nor PKA is associated with the downregulation of CCR5 gene 
expression by WTD, Pae, and Liq in rat glial cells. Quantitative RT-PCR experiments 
revealed that the decreased expression of CCR5 mRNA by WTD, Pae, and Liq was unchanged 
in the presence of LY294002 (1-10 µM) (A–C) or H89 (1-10 µM) (D–F). * and **, significantly 






Our previous study demonstrated that the expression levels of IL-1β, TNF-α, CCL2, 
and CXCL1 are significantly increased in the spinal cord dorsal horn under NP conditions, 
which may in turn cause the activation of microglia and astrocytes [32]. In this study, IL-
1β and TNF-α, but not CCL2 and CXCL1, increased the gene expression of NGF, BDNF, 
GDNF, and artemin in rat glial cells under in vitro inflammatory conditions. On the other 
hand, Sun et al. reported that CCR5 is upregulated under NP conditions, while the 
knockout of CCR5 suppresses CCI-induced NP, indicating that CCR5 is directly involved 
in the generation of NP [16]. In the present study, IL-1β, TNF-α, CCL2, and CXCL1 were 
found to augment CCR5 expression in glial cells. Thus, these results suggest that IL-1β 
and TNF-α exhibit both beneficial and adverse actions: neuroprotection due to an 
increase in NF production and the aggravation of CCR5-mediated inflammation, 
respectively, in glial cells under NP conditions. 
Previous studies have reported that NGF and/or GDNF inducers are therapeutic 
candidates for support of neuronal survival due to the stimulation of their biosynthesis, 
which results in the alleviation of NP [56, 57]. Similar to GDNF, artemin has been 
reported as a promising target for pain control [58]. In addition, it has been shown that 
NGF upregulates BDNF production through the activation of TrkA [59]. On the other 
hand, it has been reported that CCR5 plays a substantial role in neurotoxicity in the 
central nervous system [60]. In addition, NGF/BDNF-heterozygous mice have shown 
higher expression of CCR5 mRNA but lower gene expression of NGF and BDNF in the 
brain than wild-type mice [61, 62]. Furthermore, the pharmacological blockade of CCR5 
has been reported to be effective in the treatment of NP during the development and 
maintenance phases. Thus, CCR5 is likely to be a potential therapeutic target for NP 
[63]. In the present study, WTD and the identified active components Pae and Liq were 
found to increase the gene expression of NGF, BDNF, GDNF, and artemin but inhibit 
CCR5 expression in rat glial cells. In addition, the production of NGF and BDNF was 
augmented by WTD, Pae, and Liq under noninflammatory and inflammatory conditions. 




patients with NP in clinics in China [21-23], these findings allow me to speculate that 
WTD, mostly via Pae and Liq, exerts an anti-NP action by facilitating neuroprotection 
rather than neuropathy despite inflammatory conditions. 
Neurotrophic factors have been reported to exert neuroprotective actions through 
the activation of the PI3K and PKA signaling pathways, which are required for the 
regulation of glial cell apoptosis and neuronal differentiation [64-65]. In this study, WTD-, 
Pae-, and Liq-enhanced gene expression and production of NGF, BDNF, GDNF, and 
artemin were no longer detectable upon the addition of both LY294002 or H89 to rat glial 
cells, indicating that a common dual pathway of PI3K and PKA signaling is activated by 
WTD and its bioactive components to mediated the regulation of NGF, BDNF, GDNF, 
and artemin expression in rat glial cells. However, neither LY294002 nor H89 influenced 
WTD-, Pae-, or Liq-downregulated CCR5 gene expression in rat glial cells. Thus, both 
PI3K and PKA are unlikely to be involved in the agent-mediated suppression of CCR5 
expression. 
In summary, these results suggest, for the first time, that Pae and Liq are the active 
components for the WTD-mediated upregulation of NF and downregulation of CCR5 
production in rat glial cells under in vitro NP conditions mimicking the SNL animal model. 
Furthermore, it is strongly suggested that the regulation of NF expression differs from that of 
CCR5 expression in rat glial cells treated with WTD, Pae, or Liq in which the PI3K and PKA 
signaling pathways are involved. 




GENERAL DISCUSSION AND CONCLUSION 
Our previous study reported that TNF-α, IL-1β, CCL2, and CXCL1 are increased in 
the spinal cord dorsal horn of SNL mice, in which the progression of NP is enhanced [32]. 
In Chapter 2, TNF-α and IL-1β were found to induce the gene expression of not only 
NGF, BDNF, GDNF, and artemin but also CCR5 in rat glial cells. In addition, CCL2 and 
CXCL1 were found to increase the gene expression of CCR5 in glial cells, while there 
was no change in the levels of NGF, BDNF, GDNF, or artemin in TNF-α- and IL-1β-
treated cells. These findings suggest that chemokines such as CCL2 and CXCL1 are 
increased in the spinal cord in NP and substantially participate in exacerbating NP 
symptoms. Furthermore, both IL-1β and TNF-α are likely to be bifunctional modulators 
that exhibit neuroprotection due to the increase in NF production and the aggravation of 
CCR5-mediated inflammation in glial cells under NP conditions. Taken together with our 
previous report showing that WTD treatment clearly decreases the cytokine and 
chemokine expression in a dose-dependent manner [32], the alteration of cytokine and 
chemokine levels in the spinal cord may be associated with the WTD attenuation of NP 
symptoms. 
Wu-tou decoction is a classical TCM formula and consists of five plant herbs, which 
contain a series of components with multiple biological activities [24-27]. Since anti-pain 
action is the major function of WTD [35], the molecular mechanisms are not well 
understood. In Chapter 1, WTD effectively attenuated SNL-induced NP in a dose-
dependent manner without inducing any side effects in vivo. This finding is supported by 
clinical reports showing that WTD is widely used in NP patients with a cure rate higher 
than 80% [21-23]. On the other hand, it has been reported that an NGF inducer is a 
therapeutic candidate to control neuronal survival by stimulating the biosynthesis of NGF 
and BDNF, which in turn causes the alleviation of NP [61-62]. In addition, higher 
expression of CCR5 mRNA but lower gene levels of NGF and BDNF are detectable in 
the brains of NGF/BDNF-heterozygous mice compared to those in wild-type mice [63], 
suggesting that CCR5 is a crucial mediator of neurotoxicity in the central nervous system. 




BDNF but inhibited CCR5 expression in rat glial cells under inflammatory conditions. 
Therefore, the anti-pain action of WTD is likely to contribute to a relative increase in 
NGF and BDNF expression resulting in neuroprotection. 
The identification of bioactive compounds from natural products is needed to 
address the crucial components in therapeutic actions exerted by herbal formulas and 
accelerate novel natural product-based drug discovery [66]. In this regard, Chapter 1 
revealed that Pae and Liq are bioactive compounds of WTD that exhibit analgesic actions 
and anti-neuroinflammation in NP rats. To date, it has been reported that Pae and Liq 
exhibit anti-inflammatory, anti-oxidative, antidepressant, and anticancer effects [67-74]. 
As shown in Chapter 2, Pae and Liq were found to transcriptionally enhance constitutive 
and IL-1β-increased NGF, BDNF, GDNF, and artemin production in rat glial cells. In 
addition, the expression of CCR5 was suppressed by both compounds in the IL-1β-treated 
and untreated cells, and this phenomenon was similar to that observed in the WTD-treated 
cells. Thus, these results suggest, for the first time, that Pae and Liq are analgesic agents 
against NP and facilitate neurotrophic reactions. 
It has been reported that NFs exert neuroprotective actions by regulating glial cell 
apoptosis and neuronal differentiation through the activation of PI3K and PKA signaling 
[65]. As shown in Chapter 2, the WTD-, Pae-, and Liq-enhanced gene levels of NGF, 
BDNF, GDNF, and artemin were no longer detectable by adding either LY294002 or H89 
to rat glial cells. However, neither LY294002 nor H89 influenced WTD-, Pae-, and Liq-
downregulated CCR5 gene expression in the cells. Therefore, the common dual pathway 
consisting of PI3K and PKA signaling may be involved in the control of NF expression 
but not CCR5 expression, even when rat glial cells are treated with WTD, Pae, and Liq. 
Previous reports have shown that activation of CCR5 is crucial for RANTES-induced 
PI3K/AKT-mediated signaling in RAW264.7 cells [75], and inhibition of PKA downregulates 
forskolin-induced CCR5 transcription in human bone marrow progenitor cells [76]. The 
discrepancy in the findings in Chapter 2 and the aforementioned literature may partly be due 
to the cellular specificity, treatment, and observed parameters. Nonetheless, these results 




glial cells. Further experiments are needed to investigate the mechanisms underlying the 
regulatory effects of WTD, Pae, and Liq on CCR5 expression. 
In conclusion, these data provide novel evidence that WTD exerts anti-NP actions by 
predominantly increasing the production of NFs through the activation of PI3K and PKA 
signaling pathways in rat glial cells. Furthermore, Pae and Liq may function as analgesic 










Schema 1 Possible molecular mechanisms of the anti-NP actions of WTD, Pae, and Liq 
in rat glial cells. WTD, Pae, and Liq augment the expression of NGF, BDNF, GDNF, and 
artemin by activating PI3K- and PKA-dependent signaling pathways in rat glial cells under 
neuroinflammatory conditions. In contrast, the expression of CCR5, which is associated with 
the generation and development of NP, is suppressed by WTD, Pae, and Liq in a PI3K- and 
PKA-independent pathway(s). These results suggest possible mechanisms by which WTD, Pae, 
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